On October 19, 2026, Bio Essence Corp. announced the election of two new directors and a significant amendment to its corporate bylaws. The changes were approved by a majority of shareholders via written consent rather than a formal meeting.
The Company elected Xiying (Thea) Zhang and Geoff Fellows to its Board of Directors. Ms. Zhang is described as a strategic business and operations leader with over 15 years of experience overseeing business operations, manufacturing strategy, and product commercialization. Her previous roles include Senior Manager at Spyglass Pharma, Inc., and Oasis Medical, Inc. She holds a Master’s Degree in Business Administration from the University of Toledo and a Bachelor’s Degree in Engineering – Pharmaceutical Science from Nanjing University of Technology.
Mr. Fellows brings more than three decades of experience in finance, operations, compliance, and governance. He currently serves as the Chief Executive Officer of Embarcadero Accessible Multi-Family Office, where he has historically overseen the firm’s tax and legal departments. The filing notes that neither director has an arrangement or understanding regarding their appointment, nor are they a party to any material plan, contract, or arrangement.
In a separate action, the shareholders approved an amendment to the Company’s Bylaws to remove the limit on the number of Directors. Under the original Bylaws, the Board could consist of between one and three Directors. The new amendment, effective upon approval, changes the authorized number of Directors to be no less than one and no greater than ten. This change allows the Board to expand to a maximum of ten members, subject to consent by a majority of shareholders through an annual meeting, special meeting, or consent-in-lieu of meeting.
